Company will host a webcast at 10am ET on November 6, 2025, to discuss its Phase 2a study to assess efficacy, safety and ...

Federal regulators are clearing a first-of-its-kind treatment for symptoms of a rare neurodevelopmental disorder that is characterized by insatiable hunger. The Food and Drug Administration approved a ...

When 15-year-old Anna Hankins accepted the title of Miss Amazing in Chicago, the Mississippi teen was beaming not only because of the award, but also because of the opportunity to raise awareness ...

REDWOOD CITY, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment ...

The FDA granted priority review for a new drug application for an intranasal oxytocin analogue to reduce hyperphagia and behavioral distress associated with Prader-Willi syndrome, according to an ...

Saniona has gotten the go-ahead it needs to continue a midstage trial of its combination therapy for Prader-Willi syndrome (PWS), a debilitating genetic disorder that causes insatiable appetite and ...

Learn about Prader-Willi Syndrome—its causes, symptoms, diagnosis, and treatment options—to support individuals and improve ...

There is a Phase II randomized, double-blind clinical trial in the United States currently recruiting patients with Prader-Willi Syndrome (PWS) to evaluate the efficacy of cannabidiol (liquid form) ...

The exterior of the Food And Drug Administration headquarters is seen on July 20, 2020, in White Oak, Maryland. This story was originally published on BioPharma Dive. To receive daily news and ...

SAN DIEGO, Aug. 5, 2021 /PRNewswire/ -- Aardvark Therapeutics, Inc., a clinical stage biopharmaceutical company focused on developing and commercializing novel small molecule therapeutics to activate ...